CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering
VIENNA, Va.–(BUSINESS WIRE)–CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of the offering of 1,400,000 shares of its common stock at a price of $22.62 per share, for total gross proceeds of approximately $31.7 million, before deducting underwriting discounts and other offering expenses payable by the Company. Additionally, the Company has granted the underwriter a 30-day option to purchase up to 210,000 additional shares to cover over-allotments.
Kingswood Capital Markets, division of Benchmark Investments, LLC acted as sole book-running manager for the offering.
The shares of common stock described above were offered by CEL-SCI pursuant to a “shelf”…